Abstract: The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.

Abstract: The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.

Abstract: The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.

Abstract: The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.

Abstract: The present invention concerns antibodies and antigen-binding fragments of antibodies which specifically bind to and neutralize Chikungunya virus (CHIKV) and which are engineered to develop therapeutics in order to treat CHIKV disease or prevent CHIKV infection. The invention also relates to pharmaceutical compositions comprising antibodies of the invention and the use of the antibodies for the prevention and treatment of CHIKV disease.

Abstract: The present invention relates to an improved process for determining ?-secretase activity and for detecting ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase. In particular, the present invention relates to processes for the identification of a ?-secretase or of a cDNA which codes for a ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase. Another embodiment of the present invention relates to processes for the identification of substances which can inhibit the activity of ?-secretase, or a ?-secretase-like proteinase.

Abstract: The invention relates to the identification and use of the DAF-2/IR responsive sod-3 promoter. Transgenic C. elegans containing sod-3 reporter gene constructs are described which are useful for, among other things, the identification of genes or compounds capable of modulating the DAF-2/IR-akt pathway. Conditions are disclosed that increase or decrease the reporter activity, demonstrating the presence of either activators or inhibitors of the DAF-2/IR pathway.

Abstract: The invention refers to a novel C. elegans p21-activated kinase gene, the pak-3 gene, and associated loss-of-function phenotypes. These phenotypes can be used to elucidate PAK signaling pathways in C. elegans and to screen compounds that modulate PAK signaling.

Abstract: The invention refers to a novel C. elegans p21-activated kinase gene, the pak-3 gene, and associated loss-of-function phenotypes. These phenotypes can be used to elucidate PAK signaling pathways in C. elegans and to screen compounds that modulate PAK signaling.

Abstract: The present invention relates to an improved process for determining ?-secretase activity and for detecting ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase; particular embodiments of the process relate on the one hand to processes for the identification of a ?-secretase or of a cDNA which codes for a ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase, and on the other hand to processes for the identification of substances which can inhibit the activity of a ?-secretase, a subunit protein of ?-secretase, or a ?-secretase-like proteinase.

Abstract: The invention relates to the identification and use of the DAF-2/IR responsive sod-3 promoter. Transgenic C. elegans containing sod-3 reporter gene constructs are described which are useful for, among other things, the identification of genes or compounds capable of modulating the DAF-2/IR-akt pathway. Conditions are disclosed that increase or decrease the reporter activity, demonstrating the presence of either activators or inhibitors of the DAF-2/IR pathway.

Abstract: This invention provides a composition comprising an amount of a polypeptide effective to increase the life-span of cells wherein the polypeptide has the amino acid sequence of a cytosolic catalase and a suitable carrier. This invention also provides an isolated nucleic acid molecule encoding a cytosolic catalase. This invention also provides a host vector system for the production of a polypeptide having the biological activity of catalase which comprises the above-described vectors in a suitable host. This invention also provides a method for prolonging cell life, comprising: (a) linking the above-described nucleic acids to a regulatory element such that the expression of the above-described nucleic acids is under the control of the regulatory element; and (b) introducing the linked nucleic acid into cells for expression of the nucleic acid, thereby prolonging cell life.